Soru

Zorluk: OrtaInfectious Diseases

A 78-year-old woman is evaluated in a skilled nursing facility for abnormal urine characteristics. She was transferred to the facility two weeks ago for rehabilitation following an ischemic stroke. She has a chronic indwelling urethral catheter due to persistent neurogenic bladder. Today, the nursing staff noticed her urine is cloudy and has a strongly offensive odor. The patient is alert, conversant, and oriented to person and place, which represents her baseline cognitive status since the stroke. She denies suprapubic pain, flank pain, nausea, or chills. Her temperature is 37.0°C (98.6°F), blood pressure is 128/78 mm Hg, pulse is 76/min, and respirations are 14/min. Physical examination reveals a soft, non-tender abdomen and no costovertebral angle tenderness. Urinalysis shows a pH of 7.5, positive leukocyte esterase, positive nitrites, and >100 WBCs/hpf. A urine culture grows >10^5 CFU/mL of Proteus mirabilis that is sensitive to amoxicillin, ciprofloxacin, ceftriaxone, and trimethoprim-sulfamethoxazole. Which of the following is the most appropriate next step in management?

  1. A
    Oral amoxicillin
  2. Observation without antibiotic therapyCevap
  3. C
    Oral ciprofloxacin
  4. D
    Intravenous ceftriaxone
  5. E
    Daily prophylactic trimethoprim-sulfamethoxazole

Cevap

Observation without antibiotic therapy
The correct approach is observation without antibiotic therapy. This patient has asymptomatic bacteriuria (ASB), which is defined as the presence of bacteria in the urine without signs or symptoms of a urinary tract infection. In patients with chronic indwelling urinary catheters, colonization of the bladder and the development of a catheter biofilm are universal and inevitable within weeks of placement. Clinical manifestations such as cloudy, foul-smelling urine, as well as the presence of pyuria (white blood cells) and positive leukocyte esterase on urinalysis, are expected baseline findings in these patients and do NOT independently indicate a symptomatic tissue infection. Because the patient is at her baseline mental status and lacks systemic symptoms (e.g., fever, chills, hemodynamic instability) or localizing signs (e.g., flank pain, suprapubic tenderness), antibiotic therapy is strictly contraindicated. Treating ASB in this population does not decrease the incidence of future symptomatic UTIs or improve mortality. Instead, it actively contributes to the development of multidrug-resistant organisms and exposes the patient to adverse drug effects, including Clostridioides difficile infection.

Adım Adım Çözüm

1
Analyze the patient's symptoms and vital signs in the context of her chronic catheter.
The patient is afebrile, hemodynamically stable, at her neurological baseline, and lacks any localizing signs of infection (e.g., flank pain, suprapubic tenderness).
Distinguishing between asymptomatic bacteriuria (ASB) and a symptomatic urinary tract infection (UTI) relies entirely on clinical presentation, not laboratory values.
2
Evaluate the urinalysis and culture findings.
There is pyuria, malodorous urine, and >10^5 CFU/mL of bacteria, which are expected, inevitable findings due to chronic colonization of the bladder and catheter biofilm.
In chronically catheterized patients, cloudy, foul-smelling urine and pyuria do not independently diagnose an active infection and should not prompt treatment.
3
Determine the most appropriate management strategy based on infectious disease guidelines.
Observation without antibiotic therapy is indicated.
Treating ASB provides no clinical benefit, fails to permanently eradicate the bacteriuria, and actively increases the risk of multidrug-resistant organisms and Clostridioides difficile infection.

Anahtar Kavram

Asymptomatic bacteriuria (ASB) is universal in patients with chronic indwelling catheters and should not be treated with antibiotics, regardless of pyuria, malodorous urine, or positive cultures, unless systemic or localizing signs of infection are present.
Bu soruyu puanla